(PLRX) Pliant Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PLRX) Pliant Therapeutics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Pliant Therapeutics, Inc. 4P's Marketing Mix Analysis explains the company’s product offering, intended uses, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the page shows a real preview/sample of the report so you can assess style and content before buying. Purchase the full version to receive the complete ready-to-use analysis.
Product
PLN-74809, oral dual-selective inhibitor
PLN-74809 is Pliant Therapeutics’ lead investigational asset: an oral, small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins. It targets fibrotic and related diseases, matching Pliant Therapeutics’ core focus, and its oral dosing supports easier use than injectable options. As of 2026, it remains the company’s key development program in fibrosis.
3 Phase 2a trials for PLN-74809
PLN-74809 is Pliant Therapeutics, Inc.’s main value driver, now in 3 separate Phase 2a studies, so it is still in mid-stage development, not commercialization. This keeps the product in the clinical proof-of-concept phase, where safety and early efficacy data matter most. If these trials read out well, they can shift the asset toward later-stage value creation.
PLN-1474, avß1 inhibitor
PLN-1474 is Pliant Therapeutics, Inc.'s second small-molecule integrin program, built to selectively inhibit avß1 and reduce fibrotic signaling. It has completed Phase 1 testing, and Pliant Therapeutics, Inc. has studied it in liver fibrosis tied to NASH, a market that affects about 1 in 3 U.S. adults with fatty liver disease. This keeps the asset positioned for a high-need, liver-focused indication with clear clinical proof points.
2 preclinical integrin programs
Pliant Therapeutics, Inc. has 2 preclinical integrin programs, both earlier-stage bets beyond its lead fibrosis work. One targets oncology, and the other uses a monoclonal antibody approach for muscular dystrophies, including Duchenne muscular dystrophy. That gives Pliant 2 shots at longer-term upside, but both are still before human testing.
- 2 preclinical integrin programs
- 1 oncology-focused program
- 1 monoclonal antibody program for muscular dystrophy
- Both remain preclinical
Fibrosis-focused pipeline, founded 2015
Pliant Therapeutics, Inc. was founded in 2015 and keeps its product strategy centered on fibrosis and related diseases. Its pipeline is still clinical-stage, so the core "Product" in the 4P mix is a portfolio of drug candidates, not marketed therapies.
The scientific edge is integrin biology, a disease-signaling target linked to scar formation and organ damage. That focus gives Pliant a narrow but clear pipeline identity versus broader biotech players that spread capital across many platforms.
- Founded: 2015
- Status: clinical-stage
- Focus: fibrotic and related diseases
- Platform: integrin biology
Pliant’s Pipeline Still Depends on One Lead Fibrosis Asset
Pliant Therapeutics, Inc.’s Product mix is still lead-led: PLN-74809 is the main oral dual αvβ6/αvβ1 inhibitor in 3 Phase 2a studies, while PLN-1474 is the only other clinical asset after Phase 1. Two more programs remain preclinical, so the pipeline is still built on early fibrosis biology, not marketed drugs.
| Asset | Stage | Role |
|---|---|---|
| PLN-74809 | Phase 2a | Lead fibrosis asset |
| PLN-1474 | Phase 1 done | Second clinical program |
| 2 programs | Preclinical | Longer-term upside |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of Pliant Therapeutics, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Turns Pliant Therapeutics’ 4Ps into a quick, structured snapshot that eases analysis and speeds decision-making.
Reference Sources
Provides a concise, traceable list of primary sources and datasets that validate Pliant Therapeutics’ market, pricing, and competitive assumptions for faster due diligence.
Place
South San Francisco, California HQ
Pliant Therapeutics is headquartered in South San Francisco, California, putting its corporate, scientific, and development teams in the center of the Bay Area biotech cluster. South San Francisco is home to 200+ biotech and life-science companies, so the location supports talent access, lab partnerships, and faster R&D execution. For Pliant Therapeutics, that HQ base strengthens the "Place" element by keeping decision-makers close to the industry's deepest U.S. innovation pool.
United States operations
Pliant Therapeutics, Inc. is a U.S.-based biopharmaceutical company headquartered in South San Francisco, California, and its development work runs across U.S. clinical sites. This domestic footprint supports FDA-facing regulation, trial execution, and U.S. investor reporting, with 2025 filings showing ongoing U.S.-centered R&D spending and operations.
Clinical trial site network
Pliant Therapeutics, Inc. has no pharmacy channel yet; its products are placed through clinical trial sites, where enrolled patients and investigators access bexotegrast and other candidates. As a clinical-stage company with 0 commercial product sales, the site network is its real distribution path. That means access is limited to study centers, not retail pharmacies.
Direct-to-investigator model
Pliant Therapeutics, Inc. uses a direct-to-investigator model: its pipeline goes to research sites, not retail buyers. That fits a clinical-stage biopharma with 0 approved drugs and no consumer channel; the key buyers and users are clinicians, hospitals, and trial partners.
This makes the "place" strategy site-based and regulated, so access depends on trial enrollment, protocol execution, and investigator networks. The company’s reach is measured by active study sites and patient recruitment, not store count or distributor coverage.
- Research sites are the delivery channel.
- Clinicians and hospitals drive access.
- No approved drugs means no retail sales.
No commercial retail distribution
Pliant Therapeutics, Inc. has no commercial retail distribution because it has no marketed therapy, so there are no store, wholesaler, or e-commerce sales channels. Its place strategy is centered on clinical development and trial access, not product delivery. That means patient and site access matter more than shelf placement.
- No approved product to distribute
- Zero retail, wholesale, or online sales
- Focus on trial-site access
- Place supports pipeline development
Pliant Therapeutics: Clinical-Site Access Only, No Retail Sales
Pliant Therapeutics, Inc. is place-based around South San Francisco and U.S. clinical sites, not retail channels. With 0 marketed products and 0 commercial sales in 2025, access depends on trial centers, investigators, and patient enrollment.
| Place factor | Data |
|---|---|
| HQ | South San Francisco |
| Channel | Clinical sites only |
| Retail sales | 0 |
What You See Is What You Get
Pliant Therapeutics, Inc. Reference Sources
The preview shown here is the actual Pliant Therapeutics 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the full, editable document with Product, Price, Place and Promotion insights tailored to Pliant’s pipeline and market strategy.
Promotion
Investor relations updates
Pliant Therapeutics, Inc. uses investor relations as a core promotion tool because it is a clinical-stage company with no product sales in FY2025. Updates center on pipeline progress, trial milestones, and financing needs, which is where investors see value creation. For example, its communication cadence is tied to study readouts and SEC filings rather than commercial launches. That makes investor updates one of Pliant Therapeutics, Inc.’s main promotion channels.
Press releases on clinical data
Pliant Therapeutics, Inc. relies on press releases on clinical data to announce trial starts, readouts, and development updates, making them its main channel for scientific and operating news. In its latest reported year-end filing, cash and cash equivalents were $302.2 million, so each release also helps shape investor awareness of pipeline progress and cash runway.
Scientific conference presence
Pliant Therapeutics, Inc. can use scientific conferences to show bexotegrast and other fibrosis data directly to physicians, researchers, and partners. These meetings matter in fibrosis and integrin research because peer review and live Q&A can lift trust faster than ads. Strong conference visibility can also support BD talks and help move a clinical-stage asset toward wider adoption.
SEC filings and public disclosures
Pliant Therapeutics, Inc. uses SEC filings and public disclosures to reach investors and the market. As a U.S. listed company, it files 1 annual 10-K, 4 quarterly 10-Qs, and current 8-K updates each year, which detail pipeline progress, risks, cash use, and operating results. This channel is a core part of its promotion mix because it shapes how the investment community values the business.
- 10-K: full-year business and risk detail
- 10-Q: quarterly updates on cash and pipeline
- 8-K: material events and trial news
- Investor-facing, regulated, and timely
Clinical trial registry visibility
Pliant Therapeutics, Inc. uses public trial registration and protocol posting to make its studies easier to find on ClinicalTrials.gov, the U.S. registry used for federally covered trials since 2007. That visibility helps patients, investigators, and clinicians spot enrollment openings fast, and it also shows the trial design, endpoints, and status upfront. One clear benefit: transparency builds trust before data readouts.
- Shows enrollment opportunities early
- Shares protocol and endpoint details
- Supports scientific transparency
Pliant Therapeutics: Cash Runway and Trial Updates Drive Visibility
Pliant Therapeutics, Inc. promotes itself mainly through investor relations, SEC filings, and clinical press releases because it had no product sales in FY2025. Cash and cash equivalents were $302.2 million at year-end 2025, so each update also signals runway and trial progress. Scientific conferences and ClinicalTrials.gov add visibility for bexotegrast and fibrosis studies.
| Channel | FY2025 fact |
|---|---|
| Investor relations | $302.2M cash |
| Press releases | Trial milestones |
Price
No approved commercial price
Pliant Therapeutics, Inc. has no marketed product as of July 2026, so there is no approved commercial price yet. Its pipeline assets do not have retail, wholesale, or reimbursement pricing until regulators approve a product. At that point, pricing will depend on label, payer coverage, and launch strategy.
Pre-revenue product portfolio
Pliant Therapeutics, Inc. is still a clinical-stage company, so product pricing does not apply yet; it reported no product revenue in fiscal 2025 and fiscal 2026-to-date. Its economic model is R&D-led, with 2025 research and development spending of about $118 million supporting bexotegrast and other pipeline work. Any future revenue should come from FDA approval, licensing, or partnership deals, not current sales.
Trial access at no purchase price
Patients in Pliant Therapeutics, Inc. clinical studies do not pay a commercial drug price; access comes through trial enrollment and protocol rules. That means the relevant cost is sponsor-funded R&D, not patient pricing. In this model, the "price" is effectively $0 to the participant, while Pliant Therapeutics, Inc. bears the study and supply costs.
Future pricing depends on approval
Pliant Therapeutics, Inc. has no public commercial price list today, because no candidate is approved. If a product reaches market, price will be set after regulatory review and will hinge on efficacy, disease area, payer coverage, and competing treatments. In U.S. drug pricing, payer negotiation can matter as much as list price, so launch pricing would likely be reset by access and reimbursement terms.
- Approval first, then pricing
- Price depends on efficacy
- Payer coverage will shape net price
- No public commercial price list
Capital markets fund development
Pliant Therapeutics, Inc. uses a corporate capital model, not customer payments, because it is still a clinical-stage biotech with no product sales. Its "price" for development is funded through equity raises, cash, and other company-level financing, so shareholders effectively pay for R&D. This is the normal pricing structure for a pipeline-driven biotech.
- No product revenue yet
- Equity funds research
- Cash finances development
Pliant Therapeutics: No Sales Yet, Just a $118M R&D Bet
Pliant Therapeutics, Inc. has no approved product in fiscal 2025 or 2026-to-date, so there is no commercial price yet. Its 2025 R&D spend was about $118 million, showing the current model is development-led, not sales-led. Any future price will depend on FDA approval, payer access, and competition.
| Metric | 2025/2026 status |
|---|---|
| Commercial price | None yet |
| Product revenue | $0 |
| R&D spend | About $118 million in 2025 |
| Patient trial price | $0 to participants |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.